Why the study?
Does milrinone improve survival and modulate inflammation in patients with EV71-associated pulmonary edema?
Does milrinone improve survival and modulate inflammation in patients with EV71-associated pulmonary edema?
Milrinone may be an effective therapeutic agent for managing neurogenic shock and pulmonary edema in severe EV71 infection due to its inotropic, vasodilator, and immunoregulatory effects.
May support milrinone in EV71-associated pulmonary edema; leaves open need for larger prospective trials.
Enterovirus 71 (EV71) was implicated in a widespread outbreak of hand-foot-and-mouth disease (HFMD) across the Asia Pacific area since 1997 and has also been reported sporadically in patients with brain stem encephalitis. Neurogenic shock with pulmonary edema (PE) is a fatal complication of EV71 infection. Among inotropic agents, milrinone is selected as a therapeutic agent for EV71- induced PE due to its immunopathogenesis. Milrinone is a type III phosphodiesterase inhibitor that has both inotropic and vasodilator effects. Its clinical efficacy has been shown by modulating inflammation, reducing sympathetic over-activity, and improving survival in patients with EV71-associated PE. Milrinone exhibits immunoregulatory and anti-inflammatory effects in the management of systemic inflammatory responses in severe EV71 infection.
No takes yet. Share an insight, caveat, or question.
Shih-Min Wang (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: